KOREAN DRUG CO., LTD.
Founded in 1980, Korean Drug produces the cold medicine Haben and the dementia drug Neuromed, along with other CNS disease treatments.
As of 2026-10-10, KOREAN DRUG CO., LTD. has 1 Korean MFDS device approval, 172 Korean MFDS drug approvals, 12 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1980 and listed on KOSDAQ in 2000, Korean Drug is a pharmaceutical company. It produces and sells the cold medicine Haben and the dementia drug Neuromed, along with treatments for central nervous system (CNS) conditions including epilepsy, stroke, and Parkinson's disease, digestive and dermatological agents, antibiotics, and antipyretic/analgesic drugs. It has technology-transfer distribution and manufacturing agreements -- with Janssen-Cilag for Biafine Emulsion (1994) and with Gebro Pharma GmbH for Seractil Tablet (2002) -- and sells products through pharmacy, hospital, and clinic sales divisions as well as exports.
Products & technology
- HabenComprehensive cold medicine
- NeuromedDementia treatment
- Biafine EmulsionTechnology-transfer distribution product
- Seractil TabletTechnology-transfer manufacturing product
Regulatory approvals
data.go.kr172 Korean MFDS drug approvals · 1981–2026 / 1 Korean MFDS device approvals · 2014
- MFDS drugV-Terazan Tablet 20mg2026-08-25Drug · Prescription · Approval202602492
- MFDS drugK-Terazan Tab 50mg2025-09-24Drug · Prescription · Approval202502530
- MFDS drugNEUROMAGMG SOLUTION2025-08-08Drug · OTC · Notification202502072
- MFDS drugNeurogoline Tab. 10mg2025-01-17Drug · Prescription · Approval202500138
- MFDS drugNEUROCEPT DUO Tab.2024-12-23Drug · Prescription · Approval202403048
- MFDS drugGinkgo-mexin Tab. 240mg2024-11-06Drug · OTC · Notification202402627
- MFDS drugNeurogoline Tab. 30mg2024-02-29Drug · Prescription · Approval202400421
- MFDS drugGINKOMAXAM DUO Capsule2023-11-10Drug · OTC · Notification202303115
- MFDS drugHaben Herb Gold Cap.2023-10-26Drug · OTC · Notification202302998
- MFDS drugAdmed Tab 20mg2023-06-27Drug · Prescription · Approval202301957
- MFDS drugHaben-Power Gold Cap.2023-03-14Drug · OTC · Notification202300909
- MFDS drugdapasulin Tablet 10mg2023-01-26Drug · Prescription · Approval202300341
Show 68 more
- MFDS drugADMed tab. 5mg2022-01-11Drug · Prescription · Approval202200176
- MFDS drugDMPENEU Tablet(Epalrestat)Revoked2021-12-03Drug · Prescription · Notification202107785
- MFDS drugXANET Tab. 20mg2021-04-23Drug · Prescription · Approval202103357
- MFDS drugXANET Tab. 15mg2021-04-06Drug · Prescription · Approval202102954
- MFDS drugXANET Tab. 10mg2021-04-06Drug · Prescription · Approval202102955
- MFDS drugHemen Stick2021-03-04Drug · OTC · Notification202102013
- MFDS drugLIPODUO Tab. 10/10mg2021-02-18Drug · Prescription · Approval202101545
- MFDS drugLIPODUO Tab. 10/20mg2021-02-18Drug · Prescription · Approval202101546
- MFDS drugHaben Cough S Sol.2020-12-18Drug · OTC · Notification202009037
- MFDS drugHaben S Sol.2020-12-17Drug · OTC · Notification202008963
- MFDS drugHaben Col S Sol.2020-12-16Drug · OTC · Notification202008854
- MFDS drugEXOXIUM Tab. 20mg2020-11-12Drug · Prescription · Approval202007779
- MFDS drugEXOXIUM Tab. 40mg2020-11-12Drug · Prescription · Approval202007780
- MFDS drugMulti-Q10HTtabletRevoked2020-07-21Drug · OTC · Notification202005215
- MFDS drugPeptis Tab.2020-03-12Drug · OTC · Notification202001730
- MFDS drugRagilen Tab.2019-12-31Drug · Prescription · Approval201908719
- MFDS drugRagilen Tab. 0.5mg2019-12-31Drug · Prescription · Approval201908720
- MFDS drugLevocombi S Solution2019-05-21Drug · OTC · Approval201903305
- MFDS drugCleartoc CreamRevoked2019-05-08Drug · OTC · Notification201902959
- MFDS drugRopimax PD Tab. 2mg2019-03-07Drug · Prescription · Approval201901411
- MFDS drugRopimax PD Tab. 4mg2019-03-07Drug · Prescription · Approval201901416
- MFDS drugRopimax PD Tab. 8mg2019-03-07Drug · Prescription · Approval201901417
- MFDS drugMulti-Q10 PLUS Tab.2018-11-14Drug · OTC · Notification201804518
- MFDS drugHaben Herb F Cap.Revoked2018-11-02Drug · OTC · Notification201804378
- MFDS drugVirax Clear Cream2018-06-28Drug · OTC · Approval201802687
- MFDS drugPregalin Cap. 25mg2018-05-30Drug · Prescription · Approval201802254
- MFDS drugPregalin Cap. 50mg2018-05-21Drug · Prescription · Approval201802138
- MFDS drugPregalin Cap. 300mg2018-02-26Drug · Prescription · Approval201800935
- MFDS drugSilyton Soft Cap.2018-02-26Drug · OTC · Notification201800933
- MFDS drugAmiprex Gold Tab.2018-01-23Drug · OTC · Notification201800317
- MFDS drugDimensta Tab.2018-01-12Drug · Prescription · Approval201800191
- MFDS drugDuocla Neo Dry Syrup2017-10-11Drug · Prescription · Notification201707368
- MFDS drugLinopostine Tab. 10mg2017-09-29Drug · Prescription · Approval201707335
- MFDS drugSolistop Tab. 5mg2017-07-19Drug · Prescription · Approval201705755
- MFDS drugSolistop Tab. 10mg2017-07-19Drug · Prescription · Approval201705756
- MFDS drugLaxarotin Tab. 100mg2017-06-13Drug · Prescription · Approval201703447
- MFDS drugLaxarotin Tab. 50mg2017-06-13Drug · Prescription · Approval201703448
- MFDS drugStroxstar ER Cap.Revoked2017-05-17Drug · Prescription · Approval201702431
- MFDS drugMemo-Q Sol.2016-09-06Drug · OTC · Notification201605441
- MFDS drugMulsto ODF2016-06-20Drug · OTC · Notification201603600
- MFDS drugRoicoby S Solution2016-04-20Drug · OTC · Approval201602206
- MFDS drugHabenplus Nasal Spray2016-04-14Drug · OTC · Notification201602094
- MFDS drugHaben Fresh Nasal Spray2016-03-14Drug · OTC · Notification201601470
- MFDS drugTurbina Plus Cream2016-01-05Drug · OTC · Notification201600079
- MFDS drugCollodem S Liquid2015-12-29Drug · OTC · Approval201508488
- MFDS drugPenstop Soft Cap.2015-10-12Drug · OTC · Notification201507100
- MFDS drugLiposto Tab. 5mg2015-09-30Drug · Prescription · Approval201506829
- MFDS drugLiposto Tab. 10mg2015-09-30Drug · Prescription · Approval201506830
- MFDS drugBronchamin Tab.2015-09-30Drug · Prescription · Notification201506845
- MFDS drugOlotension Tab. 5/20mg2015-08-25Drug · Prescription · Approval201505939
- MFDS drugOlotension Tab. 5/40mg2015-08-25Drug · Prescription · Approval201505940
- MFDS drugOlotension Tab. 10/40mg2015-08-25Drug · Prescription · Approval201505941
- MFDS drugNeurocept ODF 10Revoked2015-08-12Drug · Prescription · Approval201505588
- MFDS drugNeurocept ODF 5Revoked2015-08-12Drug · Prescription · Approval201505589
- MFDS drugSpamed Tab.2015-07-24Drug · OTC · Notification201505055
- MFDS drugLiposto Tab. 20mg2015-06-26Drug · Prescription · Approval201504162
- MFDS drugNeuroceltec Tab.2015-06-17Drug · OTC · Notification201503940
- MFDS drugCelbric Cap.2015-03-25Drug · Prescription · Approval201501572
- MFDSIVD strip for endocrine self testRevoked2014-11-25Product approval · Class 2제허 14-2432 호
- MFDS drugHaben-Co Tab.Revoked2014-11-05Drug · OTC · Notification201405163
- MFDS drugEsoroxen Tab.2014-08-12Drug · Prescription · Approval201403728
- MFDS drugKorean Drug Co. Cefaclor Cap.2014-05-23Drug · Prescription · Approval201402355
- MFDS drugDuroprex Cap. 30mg2014-04-14Drug · Prescription · Approval201401792
- MFDS drugRheumaclo Tab.2014-02-05Drug · Prescription · Approval201400500
- MFDS drugDuroprex Cap. 60mg2013-12-30Drug · Prescription · Approval201310933
- MFDS drugZainal-Q Soft Cap.2013-12-04Drug · OTC · Notification201310498
- MFDS drugHaben US Cap.2013-10-04Drug · OTC · Notification201309581
- MFDS drugBonehyal Plus Inj.Revoked2013-09-27Drug · Prescription · Notification201309477
Showing the 80 most recent of 173 records.
Clinical trials
data.go.kr18 MFDS clinical trial authorisations · 2013–2026 (Bioequivalence 17 · Phase 4 1)
- Phase 4큐업액2026-03-18
4 trial sites
- Bioequivalence자바닉스정60밀리그램2025-06-19
1 trial site
- Bioequivalence고려보노프라잔정20밀리그램(가칭)2024-08-21
1 trial site
- Bioequivalence고려테고프라잔50밀리그램(가칭)2024-01-03
1 trial site
- Bioequivalence고려니세르골린(가칭)2023-04-20
1 trial site
- Bioequivalence리포메트정20밀리그램2021-11-23
1 trial site
- Bioequivalence자네트정20밀리그램2020-04-22
1 trial site
- Bioequivalence자네트정20밀리그램2019-10-15
1 trial site
- Bioequivalence고려라사길린정(가칭)2019-04-15
2 trial sites
- Bioequivalence로피맥스피디정2밀리그램(로피니롤염산염)2017-05-30
2 trial sites
- Bioequivalence고려베포타스틴정(베포타스틴베실산염)2016-06-24
2 trial sites
- Bioequivalence디멘스타정(콜린알포세레이트)2016-04-29
2 trial sites
Show 6 more
- Bioequivalence벤라프렉스오알정75밀리그램(벤라팍신염산염)2016-02-26
2 trial sites
- Bioequivalence리포스토정 20밀리그램2014-12-23
2 trial sites
- Bioequivalence리포메트정20밀리그램(아토르바스타틴칼슘삼수화물)2014-03-19
2 trial sites
- Bioequivalence파비도엔필름코팅정 100mg/25mg/200mg2014-03-10
2 trial sites
- Bioequivalence시타프렉스정10밀리그램(에스시탈로프람옥살산염)2013-10-14
2 trial sites
- Bioequivalence듀로프렉스캡슐60밀리그램(둘록세틴염산염)2013-06-05
2 trial sites
R&D and key agreements
Source: DART corporate disclosure신약·제네릭·건강기능식품 연구개발 · R&D handled by seven teams including QM, research planning, and formulation research
Publications
PubMed · affiliation-matched- CYP4X1 Expression Is Associated with Metastasis and Poor Prognosis in Patients with Colorectal Cancer.
International journal of molecular sciences · 2025-02 · Kim S, Kim H, Hong I 외 8
- High expression of LY6E is an independent prognostic factor of colorectal cancer patients.
Oncology reports · 2023-04 · Kim HJ, Hong I, Roh S 외 7
- Optimized self-microemulsifying drug delivery system improves the oral bioavailability and brain delivery of coenzyme Q10.
Drug delivery · 2022-12 · Chhitij T, Seo JE, Keum T 외 9
- Neuroprotective effects of Acer palmatum thumb. leaf extract (KIOM-2015E) against ischemia/reperfusion-induced injury in the rat retina.
Molecular vision · 2020-01 · Kim YH, Oh TW, Park E 외 3
- Anti-fibrotic effects of Orostachys japonicus A. Berger (Crassulaceae) on hepatic stellate cells and thioacetamide-induced fibrosis in rats.
Nutrition research and practice · 2017-12 · Koppula S, Yum MJ, Kim JS 외 6
- Anti‑inflammatory effect of Amomum xanthioides in a mouse atopic dermatitis model.
Molecular medicine reports · 2017-12 · Choi YA, Choi JK, Jang YH 외 6
- Anti-fibrotic effects of Cuscuta chinensis with in vitro hepatic stellate cells and a thioacetamide-induced experimental rat model.
Pharmaceutical biology · 2017-12 · Kim JS, Koppula S, Yum MJ 외 5
- Protective effects of Ampelopsis brevipedunculata against in vitro hepatic stellate cells system and thioacetamide-induced liver fibrosis rat model.
Pharmaceutical biology · 2017-12 · Yum MJ, Koppula S, Kim JS 외 6
- Chrysin attenuates atopic dermatitis by suppressing inflammation of keratinocytes.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2017-12 · Choi JK, Jang YH, Lee S 외 10
- Effect of Sunlight Radiation on the Growth and Chemical Constituents of Salvia plebeia R.Br.
Molecules (Basel, Switzerland) · 2017-08 · Jang HJ, Lee SJ, Kim CY 외 5
Show 2 more publications
- Salvia plebeia R.Br. inhibits signal transduction of IL-6 and prevents ovariectomy-induced bone loss by suppressing osteoclastogenesis.
Archives of pharmacal research · 2016-12 · Kim MH, Jung K, Nam KH 외 9
- Salvia plebeia extract inhibits the inflammatory response in human rheumatoid synovial fibroblasts and a murine model of arthritis.
Phytomedicine : international journal of phytotherapy and phytopharmacology · 2015-03 · Choi JK, Oh HM, Park JH 외 7
Patents
KIPRIS · applicant-matchedRegistered · 2025-04 · Application 1020250050931
Registered · 2024-03 · Application 1020240030686
Registered · 2023-02 · Application 1020230017536
Published · 2022-03 · Application 1020220027993
Registered · 2022-01 · Application 1020220010955
PCT · Published · 2020-08 · Application PCT/KR2020/010685
Registered · 2020-08 · Application 1020200101329
Rejected · 2020-08 · Application 1020200101326
EP · Published · 2018-10 · Application 18868101.9
PCT · Published · 2018-10 · Application PCT/KR2018/011971
Show 10 more patents
JP · Published · 2018-10 · Application 32542515
Registered · 2018-09 · Application 1020180115748
Registered · 2017-10 · Application 1020170135472
Registered · 2016-04 · Application 1020160045143
Registered · 2009-11 · Application 1020090112750
Expired · 1999-11 · Application 1019990050802
Expired · 1999-04 · Application 1019990012298
Rejected · 1995-07 · Application 1019950021417
Expired · 1995-07 · Application 1019950019850
Expired · 1993-02 · Application 1019930002286
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot75
- PerplexityPerplexityBot4
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KOREAN DRUG CO., LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Kwangdong Pharmaceutical, founded in 1963 and KOSPI-listed in 1989, manufactures prescription drugs and beverages.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
KOSPI-listed pharmaceutical company known for its anti-ulcer drug Noltec and leukemia treatment Supect (radotinib).
Founded in 1996 and listed on KOSDAQ in 1999, ChoA Pharmaceutical is an OTC-focused drugmaker exporting to 23 countries worldwide.
Founded in 1926 and listed on the KOSPI in 1962, Yuhan Corporation is a comprehensive pharmaceutical company known for its innovative drug Leclaza.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Vivozon Pharmaceutical, founded in 2002 and KOSDAQ-listed in 2005, makes ETC/OTC drugs and runs CMO/OEM businesses across about 190 items.
Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition